Indication
Chemotherapy-Induced Thrombocytopenia
5 clinical trials
6 products
Product
HetrombopagClinical trial
Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.Status: Not yet recruiting, Estimated PCD: 2024-09-01
Product
PlaceboClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Stage Phase Ⅲ Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets in Treatment of Chemotherapy-Induced ThrombocytopeniaStatus: Withdrawn, Estimated PCD: 2025-03-15
Product
Matching placeboClinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Avatrombopag for Persistent Chemotherapy-Induced Thrombocytopenia in Patients With Gastrointestinal Malignancies (ACT-GI)Status: Recruiting, Estimated PCD: 2025-03-30
Product
AvatrombopagProduct
Matching PlaceboClinical trial
A Randomized, Controlled Study on the Efficacy and Safety of Hetrombopag in the Treatment of Chemotherapy-induced Thrombocytopenia(CIT) in Patients With Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Product
Hetrombopag OlamineClinical trial
An Open, Single-center, Phase II Clinical Study of Hetrombopag in Secondary Prevention of XPO-1 Inhibitor Selinexor Combined With Chemotherapy Induced Thrombocytopenia in LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-05-01